1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL
    Meeting Abstract

    Davids, M. S.; Seymour, J. F.; Roberts, A. W.; Eichhorst, B.; Kipps, T. J.; Mato, A. R.; Stilgenbauer, S.; Mobasher, M.; Desai, M. B.; Potluri, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL
    Meeting Abstract

    Abramson, J. S.; Gordon, L. I.; Palomba, M. L.; Lunning, M. A.; Arnason, J. E.; Forero-Torres, A.; Wang, M.; Maloney, D. G.; Sehgal, A.; Andreadis, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist)
    Meeting Abstract

    Slovin, S. F.; Melloni, C.; Mansor-Lefebvre, S.; Neijber, A.; Roe, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression
    Meeting Abstract

    Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma
    Meeting Abstract

    Richter, J. R.; Wermke, M.; Kauh, J. S.; Back, J.; Salhi, Y.; Reddy, V.; Bayever, E.; Landgren, C. O.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab
    Meeting Abstract

    D'Angelo, S. P.; Hunger, M.; Schlichting, M.; Hennessy, M. G.; Bharmal, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive BNHL (TRANSCEND NHL 001 study)
    Meeting Abstract

    Siddiqi, T.; Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Wang, M.; Forero-Torres, A.; Maloney, D. G.; Heipel, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
    Meeting Abstract

    D'Angelo, S. P.; Russell, J. S.; Bhatia, S.; Hamid, O.; Mehnert, J. M.; Terheyden, P.; Shih, K. C.; Brownell, I.; Lebbé, C.; Lewis, K. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration
    Meeting Abstract

    Abramson, J. S.; Siddiqi, T.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Wang, M.; Forero-Torres, A.; Albertson, T.; Dehner, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save